Seedlabs

Functionome Panel-Readiness Audit

An audit for genetic labs to see if the genes on a test panel have enough evidence to be reliable.

A report-as-a-service for genetic testing labs that grades every gene on a proposed clinical panel against GO's reviewed human functionome v2.0, flagging genes whose functional evidence is too thin (only 47% of human genes are annotated in all three GO aspects) to support confident variant interpretation before the panel launches.

Biochemistry, Genetics and Molecular BiologyBiomedical Text Mining and Ontologies
Materials Science Information SystemsClinical genetic testing and molecular diagnostics

Concept

A genetic test is only as interpretable as the underlying gene knowledge. GO's new human functionome v2.0 provides, for the first time, a complete reviewed profile of functional evidence per human gene — and it also exposes how uneven that evidence is: 84% of human protein-coding genes are covered, but only 47% have annotations in all three GO aspects (molecular function, biological process, cellular component) [0].

The Functionome Panel-Readiness Audit is a per-gene grading service. A lab uploads any gene list — a candidate panel, an exome filter set, a reanalysis cohort — and receives a readiness grade for each gene computed from the functionome: three-aspect coverage, count of experimentally supported annotations, and whether the gene appears in one of the 1,571 GO-CAM causal pathway models [0]. The deliverable is a ranked table plus report-ready language: genes graded thin-evidence carry a suggested caveat (e.g., 'functional data for this gene is limited'), and the lab receives a curation-priority list showing where internal review will pay off most.

The single wedge: know before launch which genes on a panel will produce results the lab cannot confidently interpret.

Why now

  • Functionome v2.0 is new and reviewed: 84% human gene coverage and 47% three-aspect coverage (a 5-point increase over v1.0) [0] — the first per-gene evidence profile complete enough to grade real panels against.
  • Experimentally supported annotations grew 12% to 1,135,364 and GO-CAM pathway models grew roughly five-fold to 1,571 [0], so the grades are evidence-rich and will change year over year — making this a repeatable subscription audit rather than a one-off.
  • The commercial pain is concrete: genes with sparse functional evidence generate variants of uncertain significance, follow-up testing, and report disputes; grading genes pre-launch lets labs set report language and curation budgets before the first patient sample arrives.

Written by GLM · 9 Oct 2026

AI assessment

Backed by 1 paper92

A highly focused, low-friction B2B service that converts a public database update into a high-value risk-mitigation tool for clinical labs.

Evidence strength
5/5
The idea directly leverages specific, quantified metrics from the full text (84% coverage, 47% three-aspect coverage, 1,571 GO-CAM models) to create a grading system.
Market pull
4/5
Clinical labs face significant regulatory and operational costs associated with VUS (Variants of Uncertain Significance), making pre-launch risk assessment a high-value proposition.
Novelty & moat
4/5
While other ideas use GO for curation or drift tracking, this is the first to use the 'functionome' as a quality-assurance benchmark for clinical panel design.
Feasibility
5/5
The MVP is essentially a data-mapping exercise between a user's gene list and the existing GO v2.0 dataset, requiring minimal engineering.
Wedge clarity
5/5
The 'Panel-Readiness Audit' is a sharp, single-purpose entry point that solves a specific pain point (pre-launch uncertainty) before expanding.
Simplicity / focus
5/5
The product is a single, well-defined report-as-a-service rather than a complex platform or an integrated software suite.

Scored by Gemma 4 · 9 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Ambry Geneticscompany

    Designs large hereditary disease panels; per-gene readiness grades guide which genes to include and standardize evidence caveats across its clinical reports.

  • Invitae (Labcorp)company

    Maintains one of the broadest panel portfolios in the industry; the audit flags genes likely to drive uncertain-variant rates before each panel update ships.

  • ClinGenorganization

    Coordinates expert gene-disease curation across clinical domains; a functionome-derived readiness ranking helps prioritize which genes deserve expert curation effort next.

  • Fulgent Geneticscompany

    Launches new panels rapidly; a per-gene evidence grade is a cheap pre-launch QC step that directly shapes report wording.

  • Blueprint Geneticscompany

    A reporting-heavy panel vendor; disclaimers grounded in measured annotation coverage reduce report disputes and rework for its clinical customers.

Research it builds on

  1. The Gene Ontology knowledgebase in 2026
    Suzi A Aleksander, James P Balhoff, Seth Carbon et al. · 2025 · 168 citations
    All ideas from this paper →
Leave feedback
feasibility